secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134618
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC provides rinzimetostat Phase 1b dose optimization update
-------------------------------------------------------------

- Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).
- No numerical results or conclusions are disclosed in the 8-K filing itself.
- Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/0001193125-26-134618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer